• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Assessing Ardelyx (ARDX) Valuation After Mixed Long Term Shareholder Returns

    Simply Wall St·01/08/2026 14:44:19
    Listen to the news

    Ardelyx (ARDX) has drawn investor attention after recent trading, with the share price closing at US$5.83 and mixed return patterns over the past year, including gains over the past 3 months but a weaker year to date.

    See our latest analysis for Ardelyx.

    The recent 4.86% 1 day share price return adds a short term lift, but it comes against a weaker year to date share price return of 5.20% and a mixed longer record where the 3 year total shareholder return of 101.03% contrasts with a 5 year total shareholder return decline of 15.99%. This suggests momentum has cooled after a strong multi year run as investors reassess the balance between growth potential and risk.

    If Ardelyx has caught your eye, it can help to see what else is out there in healthcare. Take a look at healthcare stocks as a starting point.

    With Ardelyx trading at US$5.83 against an analyst price target of US$11.70 and an intrinsic value estimate implying a 91% discount, you have to ask: is this a genuine value gap, or is future growth already priced in?

    Most Popular Narrative Narrative: 49.7% Undervalued

    With Ardelyx last closing at US$5.83 against a most-followed fair value estimate of US$11.60, the narrative frames a sizeable valuation gap that hinges on long term earnings power and capital allocation.

    Strategic partnerships and licensing deals, including existing international collaborations (e.g., with Kyowa Kirin in Japan) and potential future EU partnerships, provide non-dilutive capital through milestones, royalties, and product supply revenues, which can bolster the company's cash flows and mitigate operational risk.

    Read the complete narrative.

    Curious what kind of revenue ramp and margin shift could support almost doubling that fair value versus today’s price? The narrative leans heavily on accelerating top line growth, a sharp swing into profitability, and a richer future earnings multiple than the broader US biotech peer group. Want to see how those moving parts fit together in the model and how much optimism is baked into each lever?

    Result: Fair Value of US$11.60 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, you still need to weigh real pressure points, including reliance on just two tenapanor products and the uncertainty around XPHOZAH’s Medicare reimbursement outcome.

    Find out about the key risks to this Ardelyx narrative.

    Build Your Own Ardelyx Narrative

    If you see the story differently, or simply want to compare your own assumptions with the data, you can build a personal Ardelyx view in minutes with Do it your way.

    A great starting point for your Ardelyx research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.

    Looking for more investment ideas?

    If Ardelyx is on your radar, consider expanding your watchlist with focused stock ideas that match how you like to build a portfolio.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.